The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

NAActive, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

June 15, 2024

Study Completion Date

April 15, 2026

Conditions
HBV InfectionChronic Hepatitis b
Interventions
DRUG

Tenofovir Amibufenamide(TMF)

TMF, 25mg QD, from baseline to 144 weeks

Trial Locations (12)

Unknown

The Second Xiangya Hospital, Central South University, Changsha

Beijing You'An Hospital, Capital Medical University, Beijing

People's Hospital of Dongyang City, Dongyang

Fuyang Second People's Hospital, Fuyang

The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province, Hangzhou

LiShui People's Hospital of Zhejiang Province, Lishui

The First Affiliated Hospital of Nanchang University, Nanchang

Jiangsu Province Hospital, Nanjin

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Shanghai

Shanghai East Hospital, Shanghai

The Fifth People's Hospital of Suzhou, Suzhou

The Fifth People's Hospital of Wuxi, Wuxi

All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

Ruijin Hospital

OTHER